Proteasomes function as the cellular “garbage disposals” responsible for degrading and recycling damaged or unneeded proteins. These molecular complexes are vital for maintaining cellular homeostasis, especially in rapidly dividing cells such as cancer cells that generate large volumes of defective or misfolded proteins. Inhibition of the proteasome pathway leads to an accumulation of protein waste, triggering cellular stress and, ultimately, apoptosis in susceptible cancer types like multiple myeloma. However, AML’s intrinsic resistance to proteasome inhibitors has long puzzled researchers and clinicians alike. The UC San Diego team’s latest research elucidates this resistance by revealing AML’s ability to activate compensatory stress-response mechanisms that bypass the blockade of proteasome activity.

Central to this resilience are two alternative degradation pathways AML cells employ: one governed by the heat shock factor 1 (HSF1) gene and the other autophagy, a self-digestive process that cells use to recycle damaged organelles and proteins. Unlike multiple myeloma cells which succumb to proteasome inhibition, AML cells deftly reroute their intracellular traffic to these secondary systems, effectively circumventing the therapeutic “roadblock.” Through this molecular detour, AML cells continue to clear toxic protein aggregates and sustain their pathogenic proliferation. Consequently, monotherapy with proteasome inhibitors fails to produce clinically meaningful responses in most AML patients.

Lead investigator Robert Signer, Ph.D., explains this biological contingency with a vivid analogy: AML cells encountering proteasome inhibition are akin to drivers rerouting around a highway construction zone via alternative exits, whereas multiple myeloma cells become trapped in gridlock. This “off-ramp” detour mechanism allows AML to maintain proteostasis under proteasome stress, a discovery that shaped the team’s approach to overcoming therapeutic resistance. By designing combinatorial interventions that simultaneously target the proteasome and these backup pathways, researchers aimed to cut off AML’s escape routes.

To this end, the study evaluated the effect of co-administering proteasome inhibitors with Lys05, a potent autophagy inhibitor. Lys05 functions by disrupting the lysosomal degradation pathway, thus impeding cellular autophagy. Experimental data derived from cultured AML patient cells demonstrated a significant reduction in cancer cell viability and colony formation, affirming that dual inhibition effectively overwhelms AML’s protein clearance systems. Moreover, in preclinical mouse models, this therapeutic strategy not only diminished disease burden but also substantially extended survival without inducing significant toxicity, underscoring its potential clinical relevance.

Kentson Lam, M.D., Ph.D., the study’s first author, emphasizes the critical advantage of this approach: it is largely mutation-agnostic. Given the broad spectrum of genetic alterations driving AML, personalized therapies targeting specific mutations benefit only subsets of patients. The dual pathway targeting demonstrated efficacy in a wide array of AML cell lines and patient-derived samples regardless of their mutational landscape, offering a more universally applicable treatment paradigm. This breakthrough moves the field closer to therapies capable of overcoming one of AML’s most vexing challenges—the extreme heterogeneity and adaptability of tumor cells.

The researchers underscore the translational potential of these findings as they pursue further identification of compounds capable of disabling AML’s multifaceted survival pathways. This includes exploring drugs that suppress HSF1-regulated stress responses, which, when combined with proteasome inhibitors and autophagy blockers, could comprehensively cripple AML’s proteostatic defenses. Such combinations have the potential to enter early-phase clinical testing, laying the groundwork for novel, more effective AML treatment regimens.

Interestingly, the team leveraged their extensive expertise in stem cell biology to inform their therapeutic strategy. Unlike multiple myeloma cells, AML cells originate from hematopoietic stem cells, imparting unique physiological traits and resilience mechanisms. Understanding the molecular circuitry that governs stem cell proteostasis illuminated the rationale for targeting multiple recycling pathways simultaneously. This cross-disciplinary insight exemplifies how fundamental biology can guide innovative cancer therapy development.

This work also challenges the conventional focus on genetic mutations as the primary targets for AML treatment, by suggesting that cancer cell metabolism and protein homeostasis represent vulnerable aspects that can be therapeutically exploited. Targeting the cell’s stress response and degradation systems disrupts the cancer cells’ ability to manage proteotoxic stress, tipping the balance towards cell death. This paradigm shift could inspire similar approaches across other malignancies marked by therapeutic resistance.

Ultimately, the significance of this research lies in its promise to expand treatment options for AML patients, many of whom currently face limited and toxic therapies. By illuminating the mechanisms of AML cell survival under proteasome inhibition and pioneering combination strategies to overcome those defenses, this study offers new hope for improving patient outcomes in a disease notorious for its lethality. The research community and medical practitioners alike eagerly anticipate further validation of these findings in clinical trials, which could herald a new era of mutation-agnostic, pathway-targeted therapies for AML.

The fight against AML continues to underscore the complexity of cancer biology but also highlights how unraveling a tumor’s survival tactics at a molecular level can yield transformative therapeutic insights. As Signer remarks, the ultimate objective is to translate scientific discovery into treatments that enhance patients’ lives—a goal that this breakthrough brings tantalizingly within reach.

Subject of Research: Acute myeloid leukemia (AML), proteasome inhibitors, autophagy mechanisms, cancer therapy resistance.

Article Title: Not specified.

News Publication Date: October 20, 2025.

References: Published in Blood, October 20, 2025.

Keywords: Myeloid leukemia, multiple myeloma, stem cells, autophagy, protease inhibitors.

AML, a heterogeneous and aggressive hematologic malignancy, has traditionally required intensive salvage chemotherapy to induce remission prior to allo-HSCT, the latter being the only curative option for many patients. This conventional approach predicates improved outcomes on the assumption that reduction of leukemic burden pre-transplant enhances post-transplant survival. The ASAP study, an acronym for “as soon as possible,” disrupts this dogma by rigorously comparing the efficacy of immediate transplantation following intensified conditioning with less aggressive disease control strategies against the traditional remission induction protocol.

The trial enrolled patients with relapsed or refractory AML characterized by poor responsiveness to initial therapy, stratifying them into two treatment arms: the standard of care (SOC) group receiving salvage chemotherapy to induce remission before allo-HSCT, and the alternative arm undergoing prompt transplantation aided by intensified conditioning regimens supplemented with non-intensive leukemia control or active monitoring. Importantly, a robust median follow-up duration of 61 months facilitated an unprecedented long-term outcome analysis, furnishing critical survival data.

Analysis revealed remarkably similar five-year overall survival (OS) rates between the cohorts: 47.5% in the SOC arm versus 46.1% in the immediate transplantation arm. While the trial could not definitively establish non-inferiority of the experimental approach, these findings unequivocally suggest that remission induction chemotherapy may not be universally necessary to achieve comparable survival results. This equivalence has profound implications for clinical decision-making, given that patients in the SOC arm endured prolonged hospitalizations—approximately one month longer—and heightened incidence of adverse events frequently associated with intensive chemotherapy regimens.

Delving deeper into prognostic determinants, the ASAP study underscores the preeminence of intrinsic disease biology, particularly age and AML genetics as classified by the European LeukemiaNet (ELN) 2022 risk criteria, in dictating transplant outcomes. Five-year OS markedly differed across risk strata irrespective of treatment arms, with favorable-risk patients achieving a 66% survival probability, intermediate-risk patients 53%, and adverse-risk patients only 34%. These stratifications reinforce existing paradigms that genetics serve as critical arbiters of therapeutic success, outweighing the benefits of remission status ahead of transplantation.

Intriguingly, when stratifying outcomes by combined ELN risk and treatment modality, patients with favorable or intermediate-risk AML undergoing immediate transplantation with watchful waiting protocols exhibited a higher three-year OS (77%) compared to those transplanted in complete remission after salvage therapy (66%). This counterintuitive result challenges conventional prognostic assumptions, suggesting certain molecular profiles may derive particular benefit from expedited transplantation strategies without extensive preconditioning chemotherapy.

The implications of these data extend beyond clinical survival statistics, emphasizing a pressing need to integrate precision medicine frameworks into transplantation protocols for AML. The ASAP findings spotlight that efforts to reduce leukemic load via cytotoxic salvage regimens prior to allo-HSCT might not confer the anticipated survival advantage, pivoting focus toward the biological characteristics of the disease itself. Consequently, personalized bridging therapies and post-transplant maintenance approaches tailored to genetic risk profiles emerge as vital areas for therapeutic innovation.

Several key insights crystallize from the ASAP trial. First, accelerated transplantation is feasible and safe for patients otherwise exposed to the toxicity and morbidity of salvage chemotherapy. Second, remission status at the time of transplant is less predictive of long-term survival than previously assumed. Third, AML genetics remain the cornerstone of risk stratification and outcome prediction, warranting integration of genomic profiling into routine treatment algorithms to guide individualized therapeutic choices.

Moreover, the study’s authors advocate for intensified research into novel bridging strategies with favorable tolerability that can synergize with allo-HSCT, especially for patients bearing adverse-risk AML, who continue to face dismal prognoses despite current treatments. These approaches might encompass targeted therapies, immunomodulatory agents, or maintenance regimens leveraging molecular vulnerabilities unique to specific leukemic clones.

The ASAP trial also serves as a testament to the power of global collaborative research networks in advancing hematologic oncology. Spearheaded by DKMS, an international non-profit organization dedicated to improving survival in blood cancer, the study exemplifies the relentless pursuit of evidence-based practices free from commercial bias. DKMS’s commitment extends beyond clinical trials to include financial support for young investigators and dissemination of findings through international platforms, fostering a fertile environment for innovation and multidisciplinary dialogue.

Looking ahead, the ASAP trial presents a compelling case for revising international treatment guidelines for AML, encouraging clinicians to consider immediate transplantation strategies when appropriate and to focus on genetic risk profiling as a principal decision-making tool. This shift promises to minimize patient exposure to the deleterious effects of high-dose chemotherapy, shorten hospitalization durations, and potentially enhance quality of life without compromising survival outcomes.

In summary, the ASAP trial redefines the therapeutic landscape for acute myeloid leukemia by demonstrating that remission induction with intensive chemotherapy is not an indispensable prerequisite for successful allogeneic stem cell transplantation in relapsed or refractory cases. Instead, patient-specific disease biology, particularly genetic risk status, holds greater prognostic weight. These revelations herald a new era of precision medicine in hematopoietic transplantation, where tailored approaches informed by molecular diagnostics and innovative bridging therapies aim to optimize outcomes and transform the standard of care in AML management.

Subject of Research: People
Article Title: Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial
News Publication Date: 30-Jul-2025
Web References: Not provided
References:
1. Stelljes, M. et al. Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial. Blood. 2025 Jul 30; blood.2025028730. doi: 10.1182/blood.2025028730
2. Stelljes, M. et al. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol. 2024;11(5):e324-e335. doi: 10.1016/S2352-3026(24)00065-6
Image Credits: © DKMS (Photo: Tobias Ebert)

Keywords: Stem cell research, Hematology, Blood cancer, Transplantation, Cell transplantation